เอกสารอ้างอิง
[1].Sadarangani, M., Marchant, A. & Kollmann, T.R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 21, 475–484 (2021).
[2].แนวทางตรวจการติดเชื้อ SARS-CoV-2 (เชื้อก่อโรค COVID-19) ด้วยการตรวจแอนติบอดี ตุลาคม 2563: https://www3.dmsc.moph.go.th/download/files/dmsc_sar.pdf.
[3]. Mascellino et al. Overview of the Main Anti-Sars-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. [Accessed 11/10/2021]; Available form:https://www.dovepress.com/getfile.php?fileID=73178#p.7.
[4].Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, et al.Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, Lancet Infect Dis., Volume 21, Issue 2, 2021, p.181-192.
[5].Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, LakkhanaWongsrisang, Natthinee Sudhinaraset, Sompong Vongpuns, et al.Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)medRxiv 2021.09.01.
[6].Nasamon Wanlapakorn,Nungruthai Suntronwong,Harit Phowatthanasathian,Ritthideach Yorsang,Thanunrat Thongmee,Preeyaporn Vichaiwattana,et . Immunogenicity of heterologous prime/boosterinactivated and adenoviral-vectored COVID-19 vaccine: real-world data. [Accessed 11/10/2021]; Available from: https://www.researchsquare.com/article/rs-785693/v1.
[7].Faculty of Medicine Siriraj Hospital, Mahidol University and Department of Medical Sciences, Ministry of Public Health. (2021). Safety and Immunological Response following Heterologous Primary Series of COVID-19 Vaccination: The preliminary report focusing on the delta variant. [Accessed 11/10/2021]; Available form: https://sicres.org/wp-content/uploads/2021/08/Poster-hetero-in-Eng_8pm.pdf.
[8].Barros-Martins J, Hammerschmidt S, Cossmann A, Odak I, Stankov MV, Ramos GM, Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey CR. Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. medRxiv. 2021 Jan 1.
[9].Madhumita Shrotri,Annalan M D Navaratnam,Vincent Nguyen,Thomas Byrne,Cyril Geismar,Ellen Fragaszy,et al Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021; (Published: July 15).